 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| CIIX Tackles Massive Epilepsy Market in China with CBD Oil-Based Pharmaceutical |
|
 Hot Stock to Watch |
Company: ChineseInvestors.com, Inc. (OTCQB: CIIX)
|
Last:
Price: 1.79
Change (%): - 0.06 (3.24)
Volume: 37,241 |
 |
ChineseInvestors.com, Inc. (CIIX) Aiming to Help Tackle Epilepsy with a CBD Oil-Based Pharmaceutical
ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.
CBD, also known as cannabidiol, is one of the most important healing substances in the hemp plant, helping treat inflammation, convulsions, insomnia, anxiety, ulcers, neuropathic pain, and epilepsy, among other medical problems. The difference between CBD and THC is that THC is classified as a federally controlled psychotropic drug, whereas CBD is recognized as not only safe but legal.
In an article entitled ‘Can Cannabis Oil Treat Seizures?’ by ConsumerReports.org, results from clinical studies in which doctors treated patients suffering from seizures with CBD showed that Cannabidiol reduced seizures by a monthly average of 36.5%, five patients no longer had motor seizures, and two patients’ seizures completely stopped.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
